To evaluate whether this interaction involved in modulating cisplatin sensitivity in cervical cancer, we then investigated the effect of suppression of PKM2 on cisplatin sensitivity with additional mTOR inhibition. This evidence concerns the gene MTOR and cervical carcinoma.